Pharmaceutical compositions containing peptides derived from human BPLP protein

Patent metadata

Field	Value
Publication number	US-9714951-B2
Application number	US-201615198262-A
Country	US
Kind code	B2
Filing date	Jun 30, 2016
Priority date	Mar 19, 2004
Publication date	Jul 25, 2017
Grant date	Jul 25, 2017

Abstract

The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated peptide,
wherein the peptide comprises the sequence Glp-Arg-Phe-Ser-Arg (SEQ ID NO: 7),
wherein the peptide is less than 15 amino acids,
wherein the peptide differs from the amino acid sequence found within human Basic Proline-rich Lacrimal Protein (SEQ ID NO:2) by two or less amino acid substitutions, and
wherein the peptide exhibits an inhibitory property against a neutral endopeptidase or an aminopeptidase-N.

2. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is a sterile injectable solution.

3. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is a time-release formulation.

4. The pharmaceutical composition of claim 1 , comprising a dose of 10-100 mg of the peptide.

5. The pharmaceutical composition of claim 4 , wherein said pharmaceutical composition is a sterile injectable solution.

6. The pharmaceutical composition of claim 4 , wherein said pharmaceutical composition is a time-release formulation.

7. The pharmaceutical composition of claim 1 , comprising a dose of 1-10 mg of the peptide.

8. The pharmaceutical composition of claim 7 , wherein said pharmaceutical composition is a sterile injectable solution.

9. The pharmaceutical composition of claim 7 , wherein said pharmaceutical composition is a time-release formulation.

10. The pharmaceutical composition of claim 1 , wherein the isolated peptide is less than 10 amino acids.

11. The pharmaceutical composition of claim 10 , wherein said pharmaceutical composition is a sterile injectable solution.

12. The pharmaceutical composition of claim 10 , wherein said pharmaceutical composition is a time-release formulation.

13. The pharmaceutical composition of claim 10 , comprising a dose of 10-100 mg of the peptide.

14. The pharmaceutical composition of claim 13 , wherein said pharmaceutical composition is a sterile injectable solution.

15. The pharmaceutical composition of claim 13 , wherein said pharmaceutical composition is a time-release formulation.

16. The pharmaceutical composition of claim 10 , comprising a dose of 1-10 mg of the peptide.

17. The pharmaceutical composition of claim 16 , wherein said pharmaceutical composition is a sterile injectable solution.

18. The pharmaceutical composition of claim 16 , wherein said pharmaceutical composition is a time-release formulation.

19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated peptide,
wherein the peptide consists of the sequence Glp-Arg-Phe-Ser-Arg (SEQ ID NO: 7), and
wherein the peptide exhibits an inhibitory property against a neutral endopeptidase or an aminopeptidase-N.

20. The pharmaceutical composition of claim 19 , wherein said pharmaceutical composition is a sterile injectable solution.

21. The pharmaceutical composition of claim 19 , wherein said pharmaceutical composition is a time-release formulation.

22. The pharmaceutical composition of claim 19 , comprising a dose of 10-100 mg of the peptide.

23. The pharmaceutical composition of claim 22 , wherein said pharmaceutical composition is a sterile injectable solution.

24. The pharmaceutical composition of claim 22 , wherein said pharmaceutical composition is a time-release formulation.

25. The pharmaceutical composition of claim 19 , comprising a dose of 1-10 mg of the peptide.

26. The pharmaceutical composition of claim 25 , wherein said pharmaceutical composition is a sterile injectable solution.

27. The pharmaceutical composition of claim 25 , wherein said pharmaceutical composition is a time-release formulation.

28. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a polymer of a peptide,
wherein the peptide comprises the sequence Glp-Arg-Phe-Ser-Arg (SEQ ID NO: 7),
wherein the peptide is less than 15 amino acids,
wherein the peptide differs from the amino acid sequence found within human Basic Proline-rich Lacrimal Protein (SEQ ID NO:2) by two or less amino acid substitutions, and
wherein the peptide exhibits an inhibitory property against a neutral endopeptidase or an aminopeptidase-N.

29. The pharmaceutical composition of claim 28 , wherein the peptide consists of the sequence Glp-Arg-Phe-Ser-Arg (SEQ ID NO: 7).

Assignees

• Pasteur Institut

Inventors

• Rougeot Catherine
• Huaulme Jean-Francois
• Ungeheuer Marie-Noelle
• Wisner Anne
• Dufour Evelyne

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P5/18

  of the parathyroid hormones · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P7/10

  Antioedematous agents; Diuretics · CPC title

• A61P35/04

  specific for metastasis · CPC title